|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,269.40 INR | -0.43% |
|
+1.72% | +11.46% |
| 08-03 | Glenmark Pharmaceuticals Limited, Q1 2027 Earnings Call, Aug 03, 2026 | |
| 07-31 | India's Glenmark Pharma posts higher quarterly profit on strong demand | RE |
Company Valuation: Glenmark Pharmaceuticals Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 131,124 | 124,718 | 131,124 | 270,463 | 434,866 | 643,164 | - | - |
| Change | - | -4.88% | 5.14% | 106.27% | 60.79% | 47.9% | - | - |
| Enterprise Value (EV) 1 | 162,310 | 150,223 | 162,699 | 263,786 | 442,540 | 595,740 | 628,691 | 595,161 |
| Change | - | -7.45% | 8.3% | 62.13% | 67.76% | 34.62% | 4.11% | -5.33% |
| P/E | 13.5x | 13.2x | 44.1x | -18x | 41.5x | 44.2x | 27.7x | 23x |
| PBR | 1.86x | 1.37x | 1.38x | 3.45x | 4.91x | 5.72x | 5.06x | 4.22x |
| PEG | - | -4.63x | -0.6x | 0x | -0x | 1.5x | 1.1x | 1.1x |
| Capitalization / Revenue | 1.2x | 1.01x | 1.01x | 2.29x | 3.26x | 3.54x | 3.83x | 3.44x |
| EV / Revenue | 1.48x | 1.22x | 1.25x | 2.23x | 3.32x | 3.51x | 3.74x | 3.18x |
| EV / EBITDA | 7.79x | 6.47x | 7.14x | 22.1x | 18.8x | 13x | 17.4x | 13.9x |
| EV / EBIT | 9.89x | 8.19x | 9.76x | 43x | 23.7x | 14.9x | 21x | 16.6x |
| EV / FCF | 45.5x | 47.2x | 923x | -22.7x | -28.1x | 28.5x | 42x | 31.4x |
| FCF Yield | 2.2% | 2.12% | 0.11% | -4.41% | -3.56% | 3.5% | 2.38% | 3.19% |
| Dividend per Share 2 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 3.82 | 4.02 |
| Rate of return | 0.54% | 0.57% | 0.54% | 0.26% | 0.16% | 0.12% | 0.17% | 0.18% |
| EPS 2 | 34.38 | 33.4 | 10.53 | -53.22 | 37.11 | 48.24 | 82.22 | 98.93 |
| Distribution rate | 7.27% | 7.49% | 23.7% | -4.7% | 6.74% | 5.18% | 4.65% | 4.06% |
| Net sales 1 | 109,439 | 123,409 | 129,901 | 118,131 | 133,217 | 169,825 | 167,925 | 187,122 |
| EBITDA 1 | 20,844 | 23,203 | 22,784 | 11,953 | 23,514 | 45,724 | 36,102 | 42,870 |
| EBIT 1 | 16,408 | 18,336 | 16,671 | 6,134 | 18,654 | 39,989 | 29,950 | 35,801 |
| Net income 1 | 9,701 | 9,936 | 2,972 | -15,017 | 10,471 | 13,619 | 23,110 | 27,707 |
| Net Debt 1 | 31,187 | 25,505 | 31,575 | -6,677 | 7,674 | -5,827 | -14,473 | -48,003 |
| Reference price 2 | 464.70 | 442.00 | 464.70 | 958.45 | 1,541.05 | 2,279.10 | 2,279.10 | 2,279.10 |
| Nbr of stocks (in thousands) | 282,168 | 282,168 | 282,168 | 282,188 | 282,188 | 282,201 | - | - |
| Announcement Date | 5/28/21 | 5/27/22 | 5/19/23 | 5/24/24 | 5/23/25 | 5/29/26 | - | - |
1INR in Million2INR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 34.6x | 3.94x | 16.78x | 0.23% | 6.76B | |
| 35.76x | 6.74x | 23.33x | 0.88% | 49.03B | |
| 20.02x | 2.36x | 10.74x | 1.29% | 42.33B | |
| 28.49x | 3.47x | 18x | 0.89% | 12.43B | |
| 26.41x | 3.9x | 15.87x | 0.6% | 11.68B | |
| 19.07x | 3.33x | 11.97x | 3.49% | 9.12B | |
| 8.53x | 2.03x | 5.28x | 5.07% | 7.15B | |
| 15.67x | 2.02x | 6.32x | 3.29% | 7.09B | |
| 41.61x | 7.97x | 29.57x | 0.95% | 4.58B | |
| Average | 25.57x | 3.97x | 15.32x | 1.85% | 16.68B | |
| Weighted average by Cap. | 26.86x | 4.27x | 16.30x | 1.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GLENMARK Stock
- Valuation Glenmark Pharmaceuticals Limited
Select your edition
All financial news and data tailored to specific country editions
